Provided by Tiger Trade Technology Pte. Ltd.

C4 Therapeutics, Inc.

3.96
-0.0450-1.12%
Volume:789.42K
Turnover:3.06M
Market Cap:486.56M
PE:-4.35
High:4.03
Open:3.97
Low:3.81
Close:4.00
52wk High:5.17
52wk Low:1.69
Shares:123.03M
Float Shares:94.52M
Volume Ratio:1.01
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9085
EPS(LYR):-1.2666
ROE:-48.14%
ROA:-19.25%
PB:1.97
PE(LYR):-3.12

Loading ...

C4 Therapeutics Q1 revenue beats estimates on Biogen milestone payment

Reuters
·
May 12

C4 Therapeutics Q1 FY26 net loss narrows to $25.1 million; revenue drops to $6.2 million

Reuters
·
May 12

BRIEF-C4 Therapeutics Q1 EPS USD -0.2 Vs. IBES Estimate USD -0.37

Reuters
·
May 12

C4 Therapeutics Q1 Revenue USD 6.2 Million VS. Ibes Estimate USD 3.33 Million

THOMSON REUTERS
·
May 12

C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewswire
·
May 12

C4 Therapeutics, Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
May 01

C4 Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 29

Jefferies Remains a Buy on C4 Therapeutics (CCCC)

TIPRANKS
·
Apr 10

C4 Therapeutics adopts Massachusetts, Delaware federal courts as exclusive forums for securities suits

Reuters
·
Apr 10

BUZZ-U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman

Reuters
·
Apr 10

C4 Therapeutics and Roche Expand Partnership with New $1 Billion-Plus Cancer Drug Deal

Deep News
·
Apr 09

C4 Therapeutics Expands Roche Collaboration with New DAC Deal

TIPRANKS
·
Apr 09

C4 Therapeutics publishes corporate presentation outlining cemsidomide, CFT8919 pipeline strategy

Reuters
·
Apr 09

C4 Therapeutics expands Roche DAC collaboration with $20 million upfront payment

Reuters
·
Apr 09

C4 Therapeutics, Inc - C4t Eligible for Tiered Royalties on Future Sales

THOMSON REUTERS
·
Apr 09

C4 Therapeutics, Inc - Agreement Covers Two Oncology Targets With Option for Third Target

THOMSON REUTERS
·
Apr 09

C4 Therapeutics, Inc - C4t to Receive $20 Mln Upfront

THOMSON REUTERS
·
Apr 09

C4 Therapeutics doses first patient in Phase 1b cemsidomide-elranatamab trial for relapsed/refractory multiple myeloma; enrollment grows to 54 patients

Reuters
·
Mar 25

C4 Therapeutics grants 85,480 inducement stock options to new employee

Reuters
·
Mar 10

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 10